Icovamenib

A small molecule inhibitor targeting mutant IDH1

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002548 | IUPAC_name = (2S)-2-[[4-(2-chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazol-2-yl]methylamino]butanamide | image = BMF-219.svg | image_size = 250px | image_alt = Chemical structure of Icovamenib }}

Icovamenib is a small molecule inhibitor that specifically targets the mutant form of the enzyme isocitrate dehydrogenase 1 (IDH1). It is being investigated for its potential use in the treatment of certain types of cancer, particularly those characterized by the presence of the IDH1 mutation.

Mechanism of Action

Icovamenib functions by inhibiting the mutant IDH1 enzyme. The IDH1 mutation leads to the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which contributes to the development and progression of cancer by altering cellular metabolism and epigenetic regulation. By inhibiting the mutant IDH1, icovamenib reduces the levels of 2-HG, thereby potentially reversing the oncogenic effects and restoring normal cellular function.

Clinical Development

Icovamenib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with cancers harboring the IDH1 mutation. These trials are crucial for determining the appropriate dosing, potential side effects, and overall therapeutic benefit of the drug.

Potential Indications

The primary focus of icovamenib's development is for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma, both of which can be associated with IDH1 mutations. The presence of these mutations in a subset of patients makes them potential candidates for targeted therapy with icovamenib.

Pharmacokinetics

The pharmacokinetic profile of icovamenib is being studied to understand its absorption, distribution, metabolism, and excretion (ADME) properties. This information is essential for optimizing dosing regimens and ensuring maximum efficacy with minimal toxicity.

Safety and Tolerability

As with any investigational drug, the safety and tolerability of icovamenib are being closely monitored in clinical trials. Common adverse effects, dose-limiting toxicities, and any serious adverse events are documented to ensure patient safety and guide future use.

Related pages

• Isocitrate dehydrogenase
• Acute myeloid leukemia
• Cholangiocarcinoma
• Targeted therapy